34 related articles for article (PubMed ID: 8023036)
1. Evaluating cancer screening programs using survival analysis.
Vratanar B; Pohar Perme M
Biom J; 2023 Oct; 65(7):e2200344. PubMed ID: 37278228
[TBL] [Abstract][Full Text] [Related]
2. Estimation of Lead Time via Low-Dose CT in the National Lung Screening Trial.
Liu R; Pérez A; Wu D
J Healthc Inform Res; 2018 Dec; 2(4):353-366. PubMed ID: 35415415
[TBL] [Abstract][Full Text] [Related]
3. The optimal starting age of endoscopic screening for esophageal squamous cell cancer in high prevalence areas in China.
Feng H; Song G; Ma S; Ma Q; Li X; Wei W; Abnet C; Qiao Y; Wang G
J Gastroenterol Hepatol; 2020 Oct; 35(10):1761-1768. PubMed ID: 32367575
[TBL] [Abstract][Full Text] [Related]
4. Bayesian lead time estimation for the Johns Hopkins Lung Project data.
Jang H; Kim S; Wu D
J Epidemiol Glob Health; 2013 Sep; 3(3):157-63. PubMed ID: 23932058
[TBL] [Abstract][Full Text] [Related]
5. Bayesian inference for the lead time in periodic cancer screening.
Wu D; Rosner GL; Broemeling LD
Biometrics; 2007 Sep; 63(3):873-80. PubMed ID: 17825017
[TBL] [Abstract][Full Text] [Related]
6. Chest X-ray screening improves outcome in lung cancer. A reappraisal of randomized trials on lung cancer screening.
Strauss GM; Gleason RE; Sugarbaker DJ
Chest; 1995 Jun; 107(6 Suppl):270S-279S. PubMed ID: 7781405
[TBL] [Abstract][Full Text] [Related]
7. Effect of length biased sampling of unobserved sojourn times on the survival distribution when disease is screen detected.
Kafadar K; Prorok PC
Stat Med; 2009 Jul; 28(16):2116-46. PubMed ID: 19424959
[TBL] [Abstract][Full Text] [Related]
8. Alternative definitions of comparable case groups and estimates of lead time and benefit time in randomized cancer screening trials.
Kafadar K; Prorok PC
Stat Med; 2003 Jan; 22(1):83-111. PubMed ID: 12486753
[TBL] [Abstract][Full Text] [Related]
9. Re: All-cause mortality in randomized trials of cancer screening.
Weiss NS; Koepsell TD
J Natl Cancer Inst; 2002 Jun; 94(11):864-5; author reply 865-6. PubMed ID: 12048281
[No Abstract] [Full Text] [Related]
10. Re: All-cause mortality in randomized trials of cancer screening.
Begg CB; Bach PB
J Natl Cancer Inst; 2002 Jun; 94(11):863-4; author reply 865-6. PubMed ID: 12048279
[No Abstract] [Full Text] [Related]
11. Lung cancer mortality in the Mayo Lung Project: impact of extended follow-up.
Marcus PM; Bergstralh EJ; Fagerstrom RM; Williams DE; Fontana R; Taylor WF; Prorok PC
J Natl Cancer Inst; 2000 Aug; 92(16):1308-16. PubMed ID: 10944552
[TBL] [Abstract][Full Text] [Related]
12. A data-analytic approach for estimating lead time and screening benefit based on survival curves in randomized cancer screening trials.
Kafadar K; Prorok PC
Stat Med; 1994 Mar 15-Apr 15; 13(5-7):569-86. PubMed ID: 8023036
[TBL] [Abstract][Full Text] [Related]
13. Screening for lung cancer. Another look; a different view.
Strauss GM; Gleason RE; Sugarbaker DJ
Chest; 1997 Mar; 111(3):754-68. PubMed ID: 9118717
[TBL] [Abstract][Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
